ArticleJournal of clinical medicine2022

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.

Paweł Rogala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.